10-K: AiXin Life International Reports FY24 Results: Revenue Declines Amidst Operational Shifts

AiXin Life International's FY24 results reveal a revenue decrease primarily due to declines in direct sales and hotel revenue, partially offset by growth in manufacturing and sales.

Summary

• AiXin Life International, a Colorado holding company operating in China, reported a net loss of $2,768,341 for the year ended December 31, 2024.
• Revenue decreased by 6% to $3,824,301 compared to $4,089,799 in 2023, driven by lower direct sales, pharmacy sales, and hotel revenue.
• The company's direct sales revenue decreased by 57% year-over-year, while pharmacy revenue declined by 12%.
• Hotel revenue experienced a 51% decrease due to relocation and leasehold improvements.
• Manufacturing and sales revenue, primarily from Yunnan Runcangsheng, increased by 139%.
• Operating costs and expenses decreased slightly to $6,412,492 from $6,588,606 in the previous year.
• The company has a working capital deficit of $6,021,163 as of December 31, 2024, raising substantial doubt about its ability to continue as a going concern.
• Management plans to improve liquidity through cost reductions, higher margin product sales, related party loans, and potential equity offerings.
• The company terminated its lease for a hotel in Jinniu District, Chengdu, and entered into a new lease for a hotel in Bandzhuyuan Town, Chengdu.
• The company is subject to various regulations in China, including those related to working conditions, employee compensation, environmental regulation, and truth in advertising.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive aspects, such as the growth in manufacturing and sales revenue, the overall sentiment is negative due to the revenue decline, net loss, and concerns about the company's ability to continue as a going concern.

Positives

• Manufacturing and sales revenue, primarily from Yunnan Runcangsheng, increased by 139% to $1,911,612.
• The company is implementing a liquidity plan to address its working capital deficit, including cost reductions and higher margin product sales.
• The company entered into a new lease for a hotel in Bandzhuyuan Town, Chengdu, which is expected to contribute to future revenue.
• The company appointed Xiaowen Zheng as Chief Financial Officer effective January 7, 2025.

Negatives

• The company reported a net loss of $2,768,341 for the year ended December 31, 2024.
• Revenue decreased by 6% to $3,824,301 compared to $4,089,799 in 2023.
• The company has a working capital deficit of $6,021,163 as of December 31, 2024, raising substantial doubt about its ability to continue as a going concern.
• Direct sales revenue decreased by 57% to $504,097, while pharmacy revenue decreased by 12% to $822,958.
• Hotel revenue decreased by 51% to $585,634 due to relocation and leasehold improvements.
• The company's auditor, KCCW Accountancy Corp., resigned effective January 7, 2025.

Risks

• The company's ability to continue as a going concern is uncertain due to its working capital deficit and net losses.
• The company's operations are subject to political, economic, and legal risks in China.
• The company is subject to foreign currency exchange rate fluctuations.
• The company is dependent on a limited number of suppliers for certain raw materials.
• The company is subject to product liability claims and product recalls.
• The company's key executive officer, Quanzhong Lin, is involved in a number of businesses and does not devote all of his working time to the company's business.
• The company's common stock may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect its auditors.

Future Outlook

The company intends to improve liquidity through cost reductions, higher margin product sales, related party loans, and potential equity offerings. It will also explore opportunities to expand its product line and acquire additional pharmacies and other retail outlets.

Industry Context

The health and wellness market in China is growing, driven by the increasing middle class and their willingness to spend on healthcare products. However, the market is also highly competitive, with various channels through which such products are marketed to consumers.

Comparison to Industry Standards

• It's difficult to compare AiXin Life International directly to industry standards due to its unique omni-channel approach and focus on the Chinese market.
• Comparable companies in the nutritional supplement space include Herbalife Nutrition and Nu Skin Enterprises, but their business models and geographic focus differ significantly.
• AiXin's reliance on direct sales and company-owned pharmacies distinguishes it from companies that primarily rely on online or retail channels.
• The company's financial performance should be assessed in the context of the specific challenges and opportunities in the Chinese market, including regulatory changes and consumer preferences.

Management Changes

Legal Proceedings

• In October, 2023, a number of individuals accused Mr. Lin, acting through Sichuan Aixin Investment Co., Ltd. and Chengdu Aixin E-commerce Co., Ltd., entities controlled by Mr. Lin, of raising funds illegally.
• All of the claims were resolved in 2024 when Mr. Lin and Aixin Zhonghong Biological Technology Co., Ltd. entered into a settlement agreement with all the claimants.
• Chengdu Public Security Bureau Jinjiang District Branch has determined to withdraw the actions and relevant withdrawal procedures are in process.
• We have been advised by counsel in the PRC that until Mr. Lin receives written confirmation that the claims have been withdrawn, we are unlikely to be able to raise funds in an offering which requires the approval of the CSRC.

Related Party Transactions

• The company has borrowed money from, loaned money to, sold products on credit to, purchased products on credit from and prepaid for certain assets or services from related parties.
• The company has office leases with related parties.

Stakeholder Impact

• Shareholders may be negatively impacted by the company's financial performance and concerns about its ability to continue as a going concern.
• Employees may be affected by cost reduction measures and potential changes in the company's operations.
• Customers may be impacted by changes in the company's product line and distribution channels.
• Suppliers may be affected by changes in the company's purchasing patterns.

Next Steps

• The company plans to implement a liquidity plan to address its working capital deficit.
• The company will explore opportunities to expand its product line and acquire additional pharmacies and other retail outlets.
• The company will continue to monitor and comply with regulations in China.
• The company will seek to obtain written confirmation that the claims against Mr. Lin have been withdrawn.

Key Dates

Keywords

revenue, net loss, financial results, pharmacy, hotel, direct sales, Yunnan Runcangsheng, China, healthcare, nutritional products, going concern, lease, auditor, Aixin Life International